Cidabendiamide (Chidamide) is a new anti-tumor drug developed independently in China and approved for marketing by the State Food and Drug Administration (CFDA) in 2014 12 for the treatment of some relapsed or refractory lymphomas.
The use of cetapenem in breast cancer is still in its relatively early stages, but the drug is one of the hot directions in oncology treatment. This article takes a brief look at the progress.
How does it work?
How does it work?
Cidarbenclamide is a histone deacetylase (HDAC) inhibitor that selectively inhibits HDAC s activation.
Under normal conditions, HDAC is involved in regulating gene expression in the body. When some cells become abnormal, HDAC can be over-activated, leading to changes in genes that regulate cell proliferation, infiltration, angiogenesis, differentiation, and more, leading to malignancy.
Sidarbenclamide also induces and activates human immune cells to kill tumors and modulates the body’s anti-tumor cell immune activity. Through a number of modulatory actions, cidabendiamide also has a potential role in restoring the sensitivity of drug-resistant tumor cells to drugs and in inhibiting tumor metastasis and recurrence.
Fighting breast cancer, starting with hormone receptor-positive patients
In in vitro studies, cetapenem showed cytotoxic effects in triple-negative breast cancer cells, inhibiting cell proliferation, blocking the cell cycle and inducing apoptosis, and reducing the invasive capacity of breast cancer cells.
Cidarbenclamide also acts synergistically in combination with other drugs. In an in vitro study, cidabenamide combined with cisplatin inhibited the proliferation of triple-negative breast cancer cells, and the combination of paclitaxel and carboplatin also inhibited the proliferation of triple-negative breast cancer cells significantly more than one chemotherapy agent alone.
All of the previously mentioned are basic in vitro studies, and the real choice when used to treat patients is hormone receptor-positive advanced breast cancer. Our investigators have conducted a III clinical trial (No. NCT02482753) that has enrolled more than 300 patients.
In this study, it was reported that cidabenamide combined with exemestane significantly prolonged progression-free survival, delayed tumor progression, and was more effective in treating patients with visceral metastases compared with exemestane alone. Moreover, patients treated with cetapenem also showed improvement in objective remission rate and clinical benefit rate. The results of the study have not yet been officially published, and we look forward to the good news that cidabendiamide will bring.
Summary
While cidabenamide has not yet been given an indication for breast cancer, phase III clinical studies suggest that endocrine agents plus cidabenamide may help control tumor progression in patients with hormone-receptor-positive advanced breast cancer.